Becker's Healthcare January 22, 2020
Maia Anderson

S&P Global Ratings released a report Jan. 21 detailing its predictions for the pharmacy benefit manager industry in 2020.

The financial services corporation said it has a negative outlook for the PBM industry this year, particularly for smaller, subscale PBMs.

Four key takeaways from the report:

  1. The risk for legislation that could hinder the PBM industry is significantly reduced in 2020, because it is an election year, according to the agency.
  2. S&P doesn’t expect proposals that would ban rebates — the discounts drugmakers pay to PBMs — to return anytime...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Market Research, Pharma, Trends
Pfizer shifts creative to Publicis in latest marketing move
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Understanding the politics of drug pricing in the United States
FDA approves Akebia anemia pill, two years after rejection

Share This Article